Inflammatory bowel disease is a serious ailment that afflicts nearly one million people in the U.S. alone. The medical management of this disorder currently includes salicylates, corticosteroids, immunosuppressive therapy, and symptomatic treatment with antidiarrheal agents, although several promising new drugs have been developed. The epidemiology, etiology, pathogenesis, and medical management of the disease are discussed in this article.
KIRSNERJB, SHORTERRGRecent developments in nonspecific inflammatory bowel disease. Part 2. N Engl J Med1982; 306: 837–48.
7.
STONNINGTONCM, PHILLIPSSF, MELTONLJ, ZINSMEISTERARChronic ulcerative colitis. Incidence and prevalence in a community. Gut1987; 28: 402–9.
8.
NORDENVALLB, BROSTROMO, BERGLUNDM, Incidence of ulcerative colitis in Stockholm County 1955-1970. Scand J Gastroenterol1985; 20: 783–90.
9.
SEDLACKRE, WHISNANTI, ELVEBACKLR, KURLANDLTIncidence of Crohn's disease in Olmsted County, Minnesota, 1935-1975. Am J Epidemiol1980; 112: 759–63.
10.
KYLEJAn epidemiological study of Crohn's disease in north-east Scotland. Gastroenterology1971; 61: 826–33.
11.
MAYBERRYJF, RHODESJ, HUGHESLEIncidence of Crohn's disease in Cardiff between 1934 and 1977. Gut1979; 20: 602–8.
12.
KYLEJ, STARKGFall in the incidence of Crohn's disease. Gut1980; 21: 240–3.
13.
SEGALI, TIMLO, HAMILTONDG, WALKERARPThe rarity of ulcerative colitis in South African blacks. Am J Gastroenterol1980; 74: 332–6.
14.
LASHNERBA, EVANSAA, KIRSNERJB, HANAUERSBPrevalence and incidence of inflammatory bowel disease in family members. Gastroenterology1986; 91: 1396–400.
15.
FARMERRG, MICHENERWM, MORTIMEREAStudies of family history among patients with IBD. Clin Gastroenterol1980; 9: 271–8.
16.
BENNETTR, RUBINPH, PRESENTDHInflammatory bowel disease in husbands and wives. Frequency of IBD in offspring in 19 couples (abstract). Gastroenterology1988; 94: A-611.
17.
DEKKER-SAEYESBJ, MEUWISSENSGM, VAN DENEMClinical characteristics and results of histocompatibility typing on 50 patients with both ankylosing spondylitis and IBD. Ann Rheum Dis1978; 37: 36–41.
18.
KIRSNERJBGenetic aspects of IBD. Clin Gastroenterol1973; 2: 557–75.
19.
MAYBERRYJF, NEWCOMBERGAre nurses at an increased risk of developing inflammatory bowel disease?Digestion1981; 22: 150–4.
20.
MILLERDS, KEIGHLEYBA, SMITHPG, HUGHESAO, LANGMANMJSA case-control method for seeking evidence of contagion in Crohn's disease. Gastroenterology1976; 71: 385–7.
21.
BURHAMWR, LENNARD-JONESJE, STANFORDJL, BIRDRGMycobacteria as a possible cause of inflammatory bowel disease. Lancet1978; 2: 693–6.
22.
CHIODINIRJ, VAN KRUININGENHJ, MERKALRS, THAYERWR, COUTUJSCharacteristics of an unclassified mycobacterium species isolated from patient's with Crohn's disease. J Clin Microbiol1984; 20: 966–71.
SHORTERRG, HUIZENGAKA, SPENCERRJA working hypothesis for the etiology and pathogenesis of nonspecific inflammatory bowel disease. Am J Dig Dis1972; 17: 1024–32.
25.
RAMPTONDS, HAWKEYCJProstaglandins and ulcerative colitis. Gut1984; 25: 1399–413.
26.
KUEHLFA, HUMESJL, HAMEA, EAGANRW, DOUGHERTYHWInflammation: the role of peroxidase-derived products. In: SamuelssonB, RamwellW, PaolettiR eds. Advances in prostaglandin and thromboxane research.New York: Raven Press, 1980: 77–86.
27.
LEWISGPImmunoregulatory activity of metabolites of arachidonic acid and their role in inflammation. Br Med Bull1983; 39: 243–8.
28.
GOULDSR, BRASHAR, CONOLLYME, LENNARD-JONESJEStudies of prostaglandins and sulphasalazine in ulcerative colitis. Prostaglandins Leukotrienes Med1981; 6: 165–82.
29.
COOPERBTSulphasalazine in inflammatory bowel disease: recent advances. NZ Med J1986; 99: 757–59.
30.
DASKM, DUBINRClinical pharmacokinetics of sulfasalazine. Clin Pharmacokinet1976; 1: 406–25.
31.
PEPPERCORNMA, GOLDMANPDistribution studies of salicylazo-sulfapyridine and its metabolites. Gastroenterology1973; 64: 240–5.
32.
AZAD KHANAK, PIRISJ, TRUELOVESCAn experiment to determine the active therapeutic moiety of sulphasalazine. Lancet1977; 2: 892–5.
33.
VAN HEESPA, BARKERJH, VAN TONGERENJHMEffects of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with iodopathic proctitis: a study to determine the active moiety of sulphasalazine. Gut1980; 21: 632–5.
34.
SHARONP, LIGUMSKYM, RACHMILEWITZD, ZORURole of prostaglandins in ulcerative colitis: enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology1978; 75: 638–40.
35.
SMITHPR, DAWSONDJ, SWANCHJProstaglandin synthetase activity in acute ulcerative colitis: effects of treatment with sulphasalazine, codeine phosphate, and prednisone. Gut1978; 20: 802–5.
36.
LIGUMSKYM, KARMELIF, SHARONP, ZORU, COHENF, RACHMILEWITZDEnhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology1981; 81: 444–9.
37.
DICKAP, GRAYSONMJ, CARPENTERRG, PETRIEAControlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut1964; 5: 437–41.
38.
BARONJH, CONNELLAM, LENNARD-JONESJE, AVERY-JONESFSulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet1962; 1: 1094–6.
39.
SUMMERSRW, SWITZDM, SESSIONSJT, National cooperative Crohn's disease study: results of drug treatment. Gastroenterology1979; 77: 847–69.
40.
WENKERTA, KRISTENSENM, EKLUNDAE, The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primary resected patients with Crohn's disease: a controlled, double-blind trial. Scand J Gastroenterol1978; 13: 161–7.
41.
DISSANAYAKEAS, TRUELOVESCA controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin). Gut1973; 14: 923–6.
42.
RIISP, ANTHONISENP, WULFFHR, FOLKENBORGO, BONNEVIEO, BINDERVThe prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment: a double-blind trial on patients asymptomatic for one year. Scand J Gastroenterol1973; 8: 71–4.
43.
KLOTZU, MAIERK, FISCHERC, HEINKELKTherapeutic efficacy of sulphasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med1980; 303: 1499–1502.
HANAUERSBMedical management of IBD. Pract Gastroenterol1988; 12: 35–49.
46.
DASKM, EASTWOODMA, MCMANUSJPA, SIRCUSWAdverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med1973; 289: 491–5.
47.
MCPHEEMS, SWANJT, BIDDLEWL, GREENBERGERNJProctocolitis unresponsive to conventional therapy: response to 5-aminosalicylic acid enemas. Dig Dis Sci1987; 32: 76S–81S.
48.
CAMPIERIM, GIONCHETTIP, BELLUZZIA, Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis. Dig Dis Sci1987; 32: 67S–70S.
49.
PATTERSONDJ, COLONYPCAntisecretory effect of sulfasalazine and 5-aminosalicylic acid in experimental colitis (abstract). Gastroenterology1983; 84: 1271.
50.
SIRCAR, JCSCHWENDERCF, CARETHERSMEInhibition of soybean lipoxygenase and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol1983; 32: 170–2.
51.
CAMPIERIM, LANFRANCHIGA, BOSCHIS, Absorption of rectally. administered 5-ASA in patients with ulcerative colitis (abstract). Gastroenterology1984; 86: 1039.
52.
BONDESENS, NIELSENOH, JACOBSENO, 5-Aminosalicylic acid enemas in patients with active ulcerative colitis. Influence of acidity on the kinetic pattern. Scand J Gastroenterol1984; 19: 677–82.
53.
Mesalamine for ulcerative colitis. Medical Lett Drugs Ther1988; 30: 30–53.
54.
KLOTZU, MAIERKEPharmacology and pharmacokinetics of 5-aminosalicyiic acid. Dig Dis Sci1987; 32: 46S–50S.
55.
CANNPA, HOLDSWORTHCDReversal of male infertility on changing treatment from sulphasalazine to 5-aminosalicylic acid (abstract). Lancet1984; 1: 1119.
56.
DEWMJ, HARRIESAD, EVANSBK, RHODESJTreatment of ulcer-ative colitis with oral S-aminosalicylic acid in patients unable to take sulphasalazine (abstract). Lancet1983; 2: 801.
57.
RASMUSSENSN, BONDESENS, HVIDBERGEF, 5-Aminosalicylic acid in a slow release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology1982; 83: 1062–70.
58.
DEWMJ, RYDERREJ, EVANSN, EVANSBK, RHODESJColonic release of 5-aminosalicylic acid from an oral preparation in active ulcerative colitis. Br J Clin Pharmacol1983; 16: 185–7.
59.
Asacol: mesalazine for ulcerative colitis. Drug Ther Bull1986; 24: 38–40.
60.
HABALFM, GREENBERGGRTreatment of ulcerative colitis with oral 5-aminosalycylic acid including patients with adverse reactions to sulfasalazine. Am J Gastroenterol1988; 83: 15–9.
61.
KLOTZU, MAIERKE, FISCHERC, BAUERKHA new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Arzneimittelforschung1985; 35: 636–9.
62.
WILLOUGHBYCP, ARONSONJK, AGBACKH, BODINNO, TRUE-LOVESCDistribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut1982; 23: 1081–7.
63.
LAURITSENK, HANSENJ, RYDEM, RASK-MADSENJColonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology1984; 86: 1496–500.
64.
IRELANDA, JEWELLDPOlsalazine in patients intolerant of sulphasalazine. Scand J Gastroenterol1987; 22: 1038–40.
65.
MEYERSS, SACHARDB, PRESENTDH, JANOWITZHDOlsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. Gastroenterology1987; 93: 1255–62.
66.
ROUTESJ, CLAMANHNCorticosteroids in inflammatory bowel disease: a review. J Clin Gastroenterol1987; 9: 529–35.
67.
PEPPERCORNMACurrent status of drug therapy for inflammatory bowel disase. Compr Ther1985; 11: 14–9.
68.
POWELL-TUCKJ, BROWNRL, CHAMBERSTJ, LENNARD-JONESJEA controlled trial of alternate-day prednisolone as a maintenance treatment for ulcerative colitis in remission. Digestion1981; 22: 263–70.
69.
MEYERSS, SACHARDB, GOLDBERGJD, JANOWITZHDCorticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. Gastroenterology1983; 85: 351–7.
70.
JONESJH, LENNARD-JONESJE, MISIEWICZJJ, PARRISHJAMulticentre trial. Betamethasone-17-valerate and prednisolone-21-phosphate retention enemata in protocolitis. Br Med J1971; 3: 84–6.
71.
WILLOUGHBYJMT, KUMARPJ, BECKETTJ, DAWSONAMControlled trial of azathioprine in Crohn's disease. Lancet1971; 2: 944–7.
72.
O'DONOGHUEDP, DAWSONAM, POWELL-TUCKJ, BROWNRLDouble-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet1978; 2: 955–7.
73.
KORELITZBIPharmacotherapy of inflammatory bowel disease. Part III: 6-mercaptopurine. Postgrad Med1983; 74: 165–72.
74.
PRESENTDH, KORELITZBI, WISCHN, GLASSJL, SACHARDB, PAS-TERNACKBSTreatment of Crohn's disease with 6-mercaptopurine. N Engl J Med1980; 302: 981–7.
75.
PRESENTDHTrends in medical therapy: metronidazole, azathioprine and 6-mercaptopurine in inflammatory bowel disease. Canad J Gastroenterology1988; 2(suppl A): 527A–62A.
76.
FRANKMS, BRANDTLJ, BERNSTEINLHPharmacotherapy of inflammatory bowel disease. Part II: metronidazole. Postgrad Med1983; 74: 155–60.
77.
BERNSTEINLH, FRANKMS, BRANDTLJ, BOLEYSJHealing of perineal Crohn's disease with metronidazole. Gastroenterology1980; 79: 357–65.
78.
URSINGB, ALMT, BAR ANYFA comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. Gastroenterology1982; 83: 550–62.
79.
TRUELOVESC, WITTSLJCortisone in ulcerative colitis. Final reports on a therapeutic trial. Br Med J1955; 2: 1041–8.
80.
CHANGKJ, CUATRECASASPHeterogeneity and properties of opiate receptors. Fed Proc1981; 40: 2729–33.
81.
KACHELG, RUPPINH, HAGELJ, BARINAW, ME1NHARDTM, DOMSCHKEWHuman intestinal motor activity and transport: effect of a synthetic opiate. Gastroenterology1986; 90: 85–93.
82.
HUGHESS, HIGGSNB, TURNBERGLAAntidiarrheal activity of loperamide: studies of its influence on ion transport across rabbit ileal mucosa in vitro. Gut1982; 23: 974–9.
83.
MCKAYJS, LINAKERBD, HIGGSNB, TURNBERGLAStudies of the antisecretory activity of morphine in rabbit ileum in vitro. Gastroenterology1982; 82: 243–7.
84.
CHANGEB, FIELDM, MILLERRJAlpha-2 adrenergic receptor regulation of ion transport in rabbit ileum. Am J Physiol1982; 242: G237–42.
MCARTHURKE, ANDERSONDS, DURBINTE, ORLOFFMJClonidine and lidamidine to inhibit watery diarrhea in a patient with lung cancer. Ann Intern Med1982; 96: 323–5.
87.
DHARMSATHAPHORNK, SHERWINRS, DOBBINSJWSomatostatin inhibits fluid secretion in the rat jejunum. Gastroenterology1980; 78: 1554–8.
88.
KVOLSLK, MOERTELCG, O'CONNELLMJ, SCHUTTAJ, RUBINJ, HAHNRGTreatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med1986; 315: 663–6.
89.
BORELJF, GUNNHCCyclosporine as a new approach to therapy of autoimmune diseases. Ann N Y Acad Sci1986; 475: 307–19.
90.
STILLERCR, LAUPACISA, KEOWNPA, Cyclosporin: action, pharmacokinetics and effect on BB rat model. Metabolism1983; 32: 69–72.
91.
KEOWNPA, ESSERYGL, STILLERCR, SINCLAIRNR, MULLENR, ULANRAMechanism of immunosuppression by cyclosporine. Transplant Proc1981; 13: 386–9.
92.
RYFFELB, GOTZV, HEUBERGERBCyclosporin receptor on human lymphocytes. J Immunol1980; 129: 1978–82.
93.
MCEVOYGK, MCQUARRIEGM eds. American hospital formulary service drug information 89.Bethesda, MD: American Society of Hospital Pharmacists, 1989: 2090–6.
94.
PARROTTHR, TAYLORRMR, VENABLESCW, RECORDCOTreatment of Crohn's disease with cyclosporin A: a report of 11 cases. Gut1980; 27: A1277–8.
95.
PELTERKIANKM, WILLIAMCN, MACDONALDAS, ROXPD, CZOLPINSKSEOpen trial of cyclosporine in patients with severe active Crohn's disease refractory to conventional therapy. Can J Gastroenterol1983; 2: 5–11.
96.
MCALLISONMC, POUNDERREEarly experience with cyclosporin for Crohn's disease (abstract). Gastroenterology1985; 88: 1304.
PORROGB, PANZAE, PETRILLOMCyclosporin A in acute ulcerative colitis. Ital J Gastroenterol1987; 19: 40–1.
99.
LAUPACISA, KEOWNPA, ULANRA, SINCLAIRNR, STILLERCRHyperbilirubinemia and cyclosporin A levels. Lancet1981; 2: 1426–7.
100.
MIHATSCHMJ, BACHJF, COOVADIAHM, Cyclosporin-associated nephropathy in patients with autoimmune disease. Klin Wochenschr1988; 66: 43–7.
101.
GUPTAS, KESHAVARZIANA, HODGSONHJFCyclosporin in ulcerative colitis. Lancet1984; 2: 1277–8.
102.
HOFFMANAF, POLEYJRCholestyramine treatment of diarrhea associated with ileal resection. N Engl J Med1969; 281: 397–401.
103.
WILLIAMSCN, DICKSONRCCholestyramine and medium-chain triglyceride in prolonged management of patients subjected to ileal resection or bypass. Can Med Assoc J1972; 107: 626–31.
104.
ELSONCO, LAYDENTJ, NEMCHAUSKYBA, ROSENBERGJL, ROSENBERGIHAn evaluation of total parenteral nutrition in the management of inflammatory bowel disease. Dig Dis Sci1980; 25: 42–8.
105.
MULLERJM, KELLERHW, ERASMIH, PICHIMAIERHTotal parenteral nutrition as the sole therapy in Crohn's disease—a prospective study. Br J Surg1983; 70: 40–3.
106.
JONESVAComparison of total parenteral nutrition and elemental diet in induction of remission of Crohn's disease. Dig Dis Sci1987; 32: 100S–7S.
107.
O'MORAINC, SEGALAW, LEVIAJElemental diet as primary treatment of acute Crohn's disease: a controlled trial. Br Med J1984; 288: 859–62.
108.
AXELSSONC, JARNUMSAssessment of the therapeutic value of an elemental diet in chronic inflammatory bowel disease. Scand J Gastroenterol1977; 12: 89–95.
109.
PRESENTDHSurgical management of IBD: traditional and innovative. Part I. Ulcerative colitis. Pract Gastroenterol1988; 12(1): 23–62.
110.
PRESENTDHSurgical management of IBD: traditional and innovative. Part II. Crohn's disease. Pract Gastroenterol1988; 12(2): 12–22.
